Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
When patients express overt racism, caregivers need to feel safe and supported. The scope of organizations’ responsibilities to make that happen needs to be clearly defined.
AMA J Ethics. 2019;21(6):E499-504. doi:
10.1001/amajethics.2019.499.